Bladder Cancer Clinical Trial

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Summary

The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and to investigate whether fesoterodine will alter the incidence of OAB/DO in these patients. Additionally, the correlation between OAB symptoms and urodynamic DO will be analyzed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men aged 30 to 90 years old with prostate adenocarcinoma who have already made their treatment selection of RARP, and only men with an AUA symptom score greater than 7 will be included. All subjects must be able to read and comprehend fully the informed consent.

Exclusion Criteria:

Men with prostate neoplasms other than adenocarcinoma
Subjects receiving other treatments for prostate cancer will be excluded.
Any subject with a preexisting bladder disease will be excluded.
Subjects with acute urinary retention and/or deceased gastrointestinal motility.
Subjects with glaucoma.
Subjects with hepatic or renal impairment.
Subjects taking CYP3A4 Inhibitors (e.g.ketoconazole, itraconazole, clarithromycin).
Subjects with myasthenia gravis
Subjects who are unwilling or unable to complete the subject questionnaires
Subjects, who in the opinion of the investigator, would be non-compliant with the majority of the visits scheduled or study procedures.

Study is for people with:

Bladder Cancer

Phase:

Phase 4

Estimated Enrollment:

3

Study ID:

NCT01661166

Recruitment Status:

Completed

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Abramson Cancer Center of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 4

Estimated Enrollment:

3

Study ID:

NCT01661166

Recruitment Status:

Completed

Sponsor:


Abramson Cancer Center of the University of Pennsylvania

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider